Mitotic rate is a count of how many cells in a tissue sample are actively dividing at the moment the tissue is examined under a microscope. It tells pathologists and oncologists how fast a tumor is growing, and in several major cancer types it directly influences the stage or grade assigned to the disease. A high mitotic rate generally signals a more aggressive tumor, while a low one suggests slower growth and, in many cases, a better prognosis. The measurement sounds straightforward, but the reality of counting dividing cells on a glass slide introduces complications that affect diagnosis, treatment decisions, and even whether two pathologists looking at the same tumor agree on what they see.
How Mitotic Rate Is Measured
When a tumor is surgically removed or biopsied, the tissue is preserved in a chemical fixative, embedded in wax, sliced into thin sections, and stained so that cellular structures become visible. Pathologists then scan the stained slide for cells caught in the act of dividing. A dividing cell looks distinct from its neighbors: its chromosomes are condensed into visible clumps or lines rather than tucked away inside a smooth nucleus. The pathologist counts how many of these mitotic figures appear within a defined area of the slide.
In most cancer types, the standard area is ten consecutive high-power fields viewed through a microscope. In breast cancer, for instance, guidelines call for counting mitoses across ten contiguous fields in the most active part of the tumor. Some researchers have tested shortcuts, like counting in a single field at the tumor’s most active edge, and found that a simplified scoring system can approximate the full ten-field count reasonably well in core biopsy specimens.1PubMed. Mitotic counts in one high power field in breast core biopsies is equivalent to counts in 10 high power fields Still, the ten-field standard remains the default in most pathology labs because it reduces the chance that a small sampling area will give a misleadingly high or low result.
For melanoma, the count is expressed as mitoses per square millimeter of tissue. For gastrointestinal stromal tumors (GISTs), it is typically reported per fifty high-power fields. These differences in units can cause confusion, but the underlying principle is the same: more dividing cells per area means faster growth.
Why Tissue Handling Matters More Than You’d Think
One of the less appreciated problems with mitotic counting is that cells do not freeze in place the instant a surgeon removes tissue. From the moment a tumor leaves the body, cells that were partway through division keep progressing. If the tissue sits on a bench for an hour or two before being placed in fixative, many of those dividing cells will have finished splitting, and their telltale appearance disappears. The result is an artificially low mitotic count.
Research going back decades has documented this effect. One study found that observable mitotic figures dropped by about half after just sixty minutes of delayed fixation, with further decline to roughly 15 percent of the original count after three hours.2Acta Pathologica Microbiologica Scandinavica Section A Pathology. MITOTIC ACTIVITY AND DELAY IN FIXATION OF TUMOUR TISSUE Another study reported a roughly 30 percent drop with a two-hour delay and a 50 percent drop after six hours.3PubMed Central. Does delay in fixation affect the number of mitotic figures in processed tissue? A separate investigation noted that the decline was not purely biological: many of the “lost” mitotic figures had actually become shrunken and distorted rather than truly completing division, making them harder to recognize rather than truly absent.4Human Pathology. Changes in mitotic rate and cell cycle fractions caused by delayed fixation
This means that two identical tumors could receive different mitotic rates simply because one was fixed promptly and the other waited in a specimen bag for a couple of hours. In routine surgical pathology, delays of that magnitude are not unusual. It is one reason why pathologists and surgeons try to minimize time-to-fixation, though the practical realities of busy operating rooms make perfection difficult.
How Pathologists Disagree on What They See
Even when tissue handling is ideal, counting mitoses is surprisingly subjective. A dividing cell is not always easy to distinguish from a dying cell or from certain artifacts introduced by tissue processing. Studies across several cancer types have found that pathologists often reach similar total counts but disagree on which specific cells qualify as mitotic figures. In one breast cancer study, pairwise agreement between pathologists on individual mitotic objects was only about two-thirds, meaning roughly a third of the figures one pathologist counted were not counted by another, and vice versa.5PLOS ONE. Mitosis Counting in Breast Cancer: Object-Level Interobserver Agreement and Comparison to an Automatic Method
A study of meningioma grading found only moderate agreement between observers when counting mitoses.6PubMed. Interobserver Variability in Mitotic Count for Meningioma Grading: How Can We Reduce It? In oral cancers, the variability was worst in poorly differentiated tumors, where the maximum difference between two observers was as high as five mitotic figures per field.7Annals of International Medical and Dental Research. To Assess the Interobserver Variability in Mitotic Figure Counting in Various Grades of Oral Squamous Cell Carcinoma These are the very tumors where the count matters most, because they tend to be aggressive and treatment decisions hinge on precise grading.
The disagreement does not mean mitotic counting is useless. Pathologists generally agree on whether a tumor has a low, moderate, or high mitotic rate. Where they diverge is at the boundaries between categories, exactly the spot where a patient might be tipped from one grade to the next. This has led to ongoing efforts to make the count more objective, including the use of special stains and artificial intelligence.
The Role of Mitotic Rate in Melanoma Staging
Melanoma is perhaps the cancer most closely associated with mitotic rate in the public mind, partly because it was once written directly into the staging rules. Under the seventh edition of the AJCC (American Joint Committee on Cancer) staging system, a mitotic rate of one or more per square millimeter was enough to bump a thin melanoma from stage T1a to T1b, a meaningful change that could affect whether a patient was offered a sentinel lymph node biopsy.
The eighth edition, published in 2017, changed this. When researchers reanalyzed data from tens of thousands of melanoma patients, they found that for thin melanomas, tumor thickness (split at 0.8 mm) and the presence of ulceration were better predictors of survival than the mitotic rate alone. As a result, T1a is now defined as a melanoma less than 0.8 mm thick without ulceration, and T1b includes those 0.8 to 1.0 mm thick (with or without ulceration) or those less than 0.8 mm with ulceration. Mitotic rate was dropped as a formal T-category criterion.8PubMed Central. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
That does not mean it stopped mattering. The AJCC still recommends that mitotic rate be recorded for every melanoma patient, because across all thickness categories it remains a strong predictor of outcomes.9PubMed Central. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care Clinicians use it alongside other factors to guide treatment discussions, even though it no longer formally changes the stage on paper.
Where Mitotic Rate Still Drives Staging Directly
In several other cancers, mitotic rate remains embedded in the staging or grading criteria and can dramatically alter a patient’s risk category.
Gastrointestinal stromal tumors rely on mitotic rate as one of their primary risk-stratification tools. The standard threshold is five mitoses per fifty high-power fields: tumors above that line are considered higher risk. In one large study, a high mitotic rate carried a hazard ratio for recurrence of about 14.6, meaning patients with actively dividing GISTs were roughly fifteen times more likely to see their cancer return after surgery than those with low-count tumors.10PubMed. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) GIST risk stratification also factors in tumor size and anatomical location, but the mitotic rate is arguably the single most consequential variable.11PubMed Central. Gastrointestinal stromal tumors: a comprehensive review
Neuroendocrine tumors of the pancreas use mitotic rate alongside a proliferation marker called Ki67 to assign a grade from G1 through G3. A G1 tumor has fewer than two mitoses per ten high-power fields and a low Ki67 index; G3 tumors exceed twenty mitoses per ten fields. The grade strongly influences whether a patient is offered surgery alone or additional systemic therapy.12PubMed Central. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3
In breast cancer, mitotic count is one of three components of the Nottingham histological grade, along with tubule formation and nuclear pleomorphism. Among these three, research on small, node-negative breast cancers found that when more sensitive cutoff points were used, the mitotic index emerged as the strongest independent predictor of survival.13PubMed Central. Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma In uterine leiomyosarcomas, a mitotic index above twenty figures per ten fields was associated with larger tumors and significantly worse prognosis.14Gynecologic Oncology. Prognostic significance of clinicopathologic parameters and biomarkers in uterine leiomyosarcomas
Not All Dividing Cells Are Equal
Pathologists have long noticed that some mitotic figures look abnormal even by the standards of a dividing cancer cell. Healthy cell division produces two neat clusters of chromosomes moving to opposite poles. In cancer, you sometimes see three or more poles (multipolar mitoses), lagging chromosomes that fail to separate properly, or other chaotic arrangements. These are collectively called atypical mitoses, and growing evidence suggests they carry independent prognostic weight.
In pancreatic cancer, roughly 30 percent of all mitoses were atypical in one study, and the presence of multipolar mitoses was an independent predictor of shorter overall survival, alongside lymph node metastasis.15PubMed. Mitotic index and multipolar mitosis in routine histologic sections as prognostic markers of pancreatic cancers: A clinicopathological study In breast cancer, the ratio of atypical to typical mitoses proved to be a more widely informative marker than the raw mitotic count. While overall mitotic score predicted survival only in the luminal molecular subtype, the atypical-to-typical ratio was significantly associated with worse outcomes in both luminal and triple-negative subtypes.16PubMed Central. The characteristics and clinical significance of atypical mitosis in breast cancer
Atypical mitoses are a sign that something has gone wrong with the cell’s quality-control machinery. Normal cells have checkpoints that halt division when chromosomes are misaligned or damaged. When those checkpoints are disabled by mutations, cells can barrel through division in sloppy fashion, producing the chaotic figures pathologists observe. This matters because it reflects underlying genetic instability, which in turn fuels the evolution of more aggressive cancer clones.
Can Technology Make the Count More Reliable?
One promising approach to the interobserver problem is staining tissue with antibodies that highlight dividing cells more clearly. Phosphohistone H3, a protein that becomes heavily modified during mitosis, lights up cells in a way that is easier to spot and harder to confuse with artifacts. A study of luminal breast cancers found that counting phosphohistone H3-positive cells was highly reproducible among observers, with substantially better agreement than the standard mitotic activity index.17PubMed Central. Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer The downside is that immunohistochemistry adds cost and turnaround time, which limits routine adoption.
Artificial intelligence is the other major frontier. Deep-learning algorithms trained on pathologist-annotated slides can scan entire tissue sections and flag mitotic figures automatically. A large validation study tested an AI model across more than 14,500 patient samples from seven different cancer types and found that automated mitotic counting correlated well with known proliferation rates. In all studied cancer types except colorectal cancer, patients with higher AI-detected mitotic counts had significantly worse outcomes.18PubMed Central. Applicability of mitotic figure counting by deep learning: a development and pan-cancer validation study A separate pilot study comparing AI-assisted counting on digital whole-slide images with traditional light-microscope counting in breast cancer found high agreement, suggesting the technology is at least as reliable as conventional methods.19PubMed Central. Deep learning supported mitoses counting on whole slide images: A pilot study for validating breast cancer grading in the clinical workflow
AI also opens a door that manual counting cannot: whole-slide analysis. When a pathologist counts under a microscope, they select what they judge to be the “hotspot” area of highest activity. But tumors are spatially heterogeneous. A melanoma study using AI to scan entire slides found that the algorithm identified hotspots with significantly higher mitotic counts than those reported in routine practice, and also revealed distinct spatial patterns of mitotic activity across different tumors, ranging from tightly clustered to relatively uniform distributions.20PubMed Central. Whole-slide analysis of mitotic activity in melanoma reveals higher-proliferation hotspots and distinct spatial patterns If the true hotspot is not where the pathologist happened to look, the conventional count underestimates the tumor’s proliferative activity. Consistent methodology for defining the counting area remains a recognized gap in the field.21Modern Pathology. Defining the area of mitoses counting in invasive breast cancer using whole slide image
How Mitotic Rate Connects to Treatment
Beyond staging and prognosis, mitotic rate has a direct link to how well certain therapies work. Many chemotherapy drugs, particularly the taxane family used in breast, lung, and ovarian cancers, kill cancer cells by disrupting the mechanical structures that pull chromosomes apart during division. Cells with high mitotic rates are constantly entering and re-entering division, which means there are more opportunities for these drugs to catch them in a vulnerable state. Cells that are dividing slowly or sitting in a quiescent phase are largely invisible to these agents.
Research into the mechanics of this relationship has shown that taxane drugs like docetaxel bind to tubulin and disrupt microtubule dynamics, trapping cells in a prolonged mitotic arrest. Some cells die in that arrested state; others undergo “mitotic slippage,” exiting mitosis without properly dividing and re-entering the cell cycle as abnormal cells.22PubMed Central. BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis Tumors with more cells in active mitosis present more targets for this mechanism, which is part of why high-grade, rapidly dividing tumors sometimes respond more dramatically to chemotherapy than their low-grade counterparts, even though they carry a worse overall prognosis.
This paradox is familiar to oncologists: a fast-growing tumor is more dangerous but can also be more chemosensitive. Mitotic rate helps quantify that dynamic and contributes to decisions about whether the potential benefit of aggressive chemotherapy justifies the side effects for a given patient.
Mitotic Rate in Veterinary Oncology
The usefulness of mitotic rate as a prognostic tool extends beyond human medicine. In veterinary pathology, it plays a strikingly similar role, particularly in canine cancers. Cutaneous mast cell tumors, one of the most common skin cancers in dogs, illustrate this clearly. A study of these tumors found that dogs whose tumors had five or fewer mitoses per ten high-power fields had a median survival of 70 months, while dogs with counts above five had a median survival of just two months, regardless of the tumor’s histological grade. Even among intermediate-grade tumors, where grade alone made prognosis uncertain, the mitotic index reliably separated long survivors from dogs that died quickly.23PubMed. Mitotic index is predictive for survival for canine cutaneous mast cell tumors
The veterinary data reinforces a broader biological point: how fast tumor cells divide is one of the most fundamental indicators of malignant behavior across species. It is not specific to any single cancer type or organ system. When a tumor’s growth rate accelerates beyond what normal tissue repair would produce, the consequences, including local invasion, metastasis, and resistance to the body’s immune defenses, tend to follow in proportion.